The effects of the primary psychoactive constituent of marijuana, ⌬ 9 -tetrahydrocannabinol, are mediated by cannabinoid receptors, CB1 and CB2. The CB1 receptors display a unique central nervous system (CNS) distribution and are present in mammalian brain at higher levels than most other known G-protein-coupled receptors. The highest levels occur in several areas involved in motor control and hippocampus. Cannabinoid effects on CNS activities, including movement, memory, nociception, endocrine regulation, thermoregulation, sensory perception, cognitive functions, and mood, correlate with the regional distribution of cannabinoid receptors and their activation of specific G-proteinmediated signal transduction systems in various brain regions.
INTRODUCTION: CANNABINOID RECEPTORS IN BRAIN
Documentation of cannabis use dates back nearly 5000 years (1). In current times, cannabis and its primary active constituent, ⌬ 9 -tetrahydrocannabinol (⌬ 9 -THC) 2 (2), are not only important as drugs of abuse, but are also being investigated for potential therapeutic applications. Until the mid-1980s, there was uncertainty over the existence of specific cannabinoid receptors. Due largely to the highly lipophilic nature of cannabinoid ligands, changes in membrane fluidity appeared to mediate many of the actions of cannabinoids (3). The first evidence for specific cannabinoid receptors came from Howlett and colleagues, who reported that cannabinoid inhibition of cyclic adenosine monophosphate (cAMP) accumulation strongly indicated a G-protein-coupled receptormediated mechanism (4). The cannabinoid receptor was first characterized by in vitro binding with the development of the high-affinity synthetic cannabinoid [ 3 H]CP 55940 (5). Soon after, the first cannabinoid receptor gene was cloned (6) and brain cannabinoid receptors were mapped autoradiographically (7). When cannabinoid receptors were identified, it was found that these receptors are distributed throughout the central nervous system of mammals (8-10) in greater abundance than most other known G-protein-coupled receptors (7). In fact, the abundance of G-proteincoupled cannabinoid receptors in brain rivals that of ionotropic glutamate receptors, which mediate the primary excitatory neurotransmission of the brain. The discovery of a specific cannabinoid receptor, along with the report of anandamide as an endogenous ligand (11) and synthesis of SR141716A as a selective receptor antagonist (12), have greatly advanced the understanding of the functional neuroanatomy of brain cannabinoid effects.
To date, two genes encoding cannabinoid receptors have been identified. The first, CB1 (6), is distributed throughout the brain and is found in several peripheral organs of the body (13). Because CB1 is the predominant type of cannabinoid receptor in the cen-1 To whom correspondence should be addressed. 2 Abbreviations used: CNS, central nervous system; cAMP, cyclic adenosine monophosphate; PTX, pertussis toxin; BS, brain stem; Cblm, cerebellum; C-P, caudate-putamen; Ctx, cerebral cortex; EP, entopeduncular nucleus; GPe/GPi, external and internal segments of the globus pallidus; Hipp, hippocampus; MBH, medial basal hypothalamus; POA, preoptic area; SNr, substantia nigra pars reticulata; STN, subthalamic nucleus; Thal, thalamus; VPL, ventroposterolateral nucleus of the thalamus; ACTH, adrenocorticotropic hormone; CRH, corticotropin-releasing hormone; FSH, folliclestimulating hormone; GH, growth hormone; GnRH, gonadotropinreleasing hormone; LH, luteinizing hormone; PRL, prolactin; TSH, thyrotropin.
